(Q36212906)

12 August 2017

1 reference

title

Antiemetic guidelines: are they being used? (English)

1 reference

12 August 2017

Rolf Kaiser

1

1 reference

12 August 2017

publication date

1 August 2005

1 reference

Lancet Oncology Commission

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

622-625

1 reference

Cancer therapy, vomiting, and antiemetics.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

The area postrema and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Internists' attitudes about clinical practice guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Does attribution theory explain physicians' nonacceptance of clinical practice guidelines?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Attributes of clinical guidelines that influence use of guidelines in general practice: observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Attributes of clinical recommendations that influence change in practice following audit and feedback

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

From best evidence to best practice: effective implementation of change in patients' care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Changing clinical behaviour by making guidelines specific

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Why don't physicians follow clinical practice guidelines? A framework for improvement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Changing physician performance. A systematic review of the effect of continuing medical education strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Continuing medical education and the physician as a learner: guide to the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Changing physicians' behavior. The pot and the kettle

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

Changing physicians' practices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970284-9

7 January 2021

10.1016/S1470-2045(05)70284-9

Identifiers

DOI

1 reference

12 August 2017

1 reference